Dr Cheryl L Barton is an independent consultant with over 35 years' research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for a variety of CNS research projects. Dr Barton joined Dutch investment bank ABN Amro NV as a senior equity analyst to provide coverage on pan-European companies and assessed the potential impact of new drug development on European Stocks. In 2002, Dr Barton founded PharmaVision to provide independent, tailor-made, life science and consumer health research to pharmaceutical companies, competitive intelligence specialists, investment institutions, and healthcare communication agencies. Dr. Barton regularly writes articles for Pharmtech regarding the latest advances in scientific technologies and regulatory issues that impact the Biopharma and MedTech industries.